Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC 94 Forward PE Ratio is 24.99 as of Jul. 25, 2026. GuruFocus rates CHIX:GMABC with a GF Score™ of 94/100 and a GF Value™ of kr2,348.08 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 355 Biotechnology companies, Genmab AS ranks worse than 55.21% on this metric.
Genmab AS (CHIX:GMABc) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Genmab AS Forward PE Ratio Related Terms
Genmab AS Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Genmab AS's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS Forward PE Ratio Chart
Genmab AS Annual Data
Trend
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
64.52
53.19
47.85
33.00
21.69
15.47
19.60
Genmab AS Quarterly Data
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
43.29
64.52
70.42
31.55
58.14
53.19
81.30
104.17
53.76
47.85
47.85
41.49
30.12
33.00
36.50
42.37
26.95
21.69
26.67
22.57
16.84
15.47
13.42
13.80
14.85
19.60
18.54
CHIX:GMABC vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Genmab AS's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Genmab AS (CHIX:GMABC) has a Forward PE Ratio of 24.99 as of Jul. 25, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #196 out of 355 companies in the Biotechnology industry, placing it in the top 55.2%.
Is Genmab AS's Forward PE Ratio too high?
Genmab AS's current Forward PE Ratio is 24.99. The Biotechnology industry median Forward PE Ratio is 21.68. Genmab AS's value of 24.99 is 15.3% above this industry median. Based on the distribution chart, Genmab AS ranks #196 out of 355 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #196 out of 355 companies for Forward PE Ratio. This places Genmab AS in the lower half of its industry. The industry median Forward PE Ratio is 21.68. Genmab AS's value of 24.99 is 15.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.68, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current Forward PE Ratio of 24.99 is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Forward PE Ratio is 24.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,348.08, compared to a current price of kr1,898.00 — trading 19.2% below its estimated fair value. The current Forward PE Ratio is 24.99 and 15.3% above the Biotechnology industry median of 21.68. Genmab AS's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Forward PE Ratio is 24.99 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr1,898.00 is trading 19.2% below its estimated GF Value™ of kr2,348.08.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
Forward PE Ratio: 24.99
GF Value™: kr2,348.08 vs. price of kr1,898.00 (19.2% below fair value)
Industry Position: 15.3% above the Biotechnology median (#196 of 355)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
94GF Score
Get the complete analysis for CHIX:GMABC
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
